NAV-002
Solid Tumors (FOLR1+)
Key Facts
About Navrogen
Navrogen is a private, preclinical-stage biotech pioneering a novel approach in immuno-oncology by targeting tumor-derived immunosuppressive proteins that inhibit humoral immunity. The company leverages its proprietary BRITE (Block-Removed Immunoglobulin Technology) and HIO screening platforms to develop a pipeline of next-generation therapeutics, including refractory antibodies, ADCs, bispecifics, and small molecule immune activators. With a focus on overcoming resistance to existing antibody therapies like rituximab and Herceptin, Navrogen aims to enhance the efficacy of cancer treatments for patients whose tumors produce specific HIO factors. The company is actively securing intellectual property for its platform and lead candidates.
View full company profile